Conatus Pharmaceuticals (CNAT) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts CNAT Hot Sheet
Join SI Premium – FREE
Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q2 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
